Taken together, these results indicated that S4 treatment enhanced the efficacy of radiotherapy on ESCC progression in vivo by inhibiting the expression of CAIX and modulating tumor microenvironment. This evidence concerns the gene CA9 and esophageal squamous cell carcinoma.